Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Bisphosphonates in the treatment of osteoporosis.

Poole KE, Compston JE.

BMJ. 2012 May 22;344:e3211. doi: 10.1136/bmj.e3211. No abstract available.

PMID:
22619192
2.

Osteonecrosis of the jaw is becoming more common.

Loukota RA.

BMJ. 2012 Sep 10;345:e5988; author reply e5990. doi: 10.1136/bmj.e5988. No abstract available.

PMID:
22963942
3.

Review overemphasises benefits and downplays serious harms.

Musini V, Mintzes B, Tejani A, Wright JM.

BMJ. 2012 Sep 10;345:e5989; author reply e5990. doi: 10.1136/bmj.e5989. No abstract available.

PMID:
22963943
4.

[New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].

Yamaguchi T, Sugimoto T.

Clin Calcium. 2009 Jan;19(1):38-43. doi: CliCa09013843. Review. Japanese.

PMID:
19122263
5.

Osteoporosis treatment after hip fracture: slow progress.

Pullman-Mooar S, Mooar P.

J Clin Rheumatol. 2005 Apr;11(2):65-7. No abstract available.

PMID:
16357704
6.

Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.

Berto P, Maggi S, Noale M, Lopatriello S.

Aging Clin Exp Res. 2010 Apr;22(2):179-88. doi: 10.3275/6816. Epub 2010 Feb 9.

PMID:
20145427
7.

[Influence on atherosclerosis of improvement of bone mineral density after medication for osteoporosis].

Yamada S, Inaba M, Nishizawa Y.

Nihon Rinsho. 2007 Nov 28;65 Suppl 9:348-51. Review. Japanese. No abstract available.

PMID:
18161129
8.

Alendronate for the treatment of osteoporosis in men.

Olszynski WP, Davison KS.

Expert Opin Pharmacother. 2008 Feb;9(3):491-8. doi: 10.1517/14656566.9.3.491 . Review.

PMID:
18220499
9.

The patient's page. Bone health facts.

McKinney J.

South Med J. 2005 Oct;98(10):1058. No abstract available.

PMID:
16295830
10.
11.

Undertreatment after hip fracture: a retrospective study of osteoporosis overlooked.

Davis JC, Ashe MC, Guy P, Khan KM.

J Am Geriatr Soc. 2006 Jun;54(6):1019-20. No abstract available.

PMID:
16776813
12.

Preventing the next "bone event".

Adler RA.

J Am Geriatr Soc. 2010 Apr;58(4):762-4. doi: 10.1111/j.1532-5415.2010.02778.x. No abstract available.

PMID:
20398160
13.

Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan.

Lin TC, Yang CY, Yang YH, Lin SJ.

Clin Pharmacol Ther. 2011 Jul;90(1):109-16. doi: 10.1038/clpt.2011.62. Epub 2011 Apr 27.

PMID:
21525868
14.

[Bone quality].

Ito M.

Nihon Rinsho. 2009 May;67(5):921-5. Review. Japanese.

PMID:
19432110
15.

How soon after hip fracture surgery should a patient start bisphosphonates?

Seton M.

Cleve Clin J Med. 2010 Nov;77(11):751-5. doi: 10.3949/ccjm.77a.10045. No abstract available.

PMID:
21048049
16.

[Pharmaceutical treatment for patients with hip fracture].

Hagino H.

Clin Calcium. 2010 Sep;20(9):1394-400. doi: CliCa100913941400. Review. Japanese.

PMID:
20808048
17.

Secondary prophylaxis of osteoporotic fractures in an orthogeriatric service.

Kenealy H, Paul S, Walker K, Garg A.

Australas J Ageing. 2011 Mar;30(1):41. doi: 10.1111/j.1741-6612.2011.00510.x. No abstract available.

PMID:
21395941
18.

[Osteoporotic fracture in menopausal women: alendronate reduces the risk].

Bize R, Lamy O, Peytremann-Bridevaux I.

Rev Med Suisse. 2008 Dec 10;4(183):2703. French. No abstract available.

PMID:
19157286
19.

Hip and subtrochanteric or diaphyseal femoral fractures in alendronate users: a 10-year, nationwide retrospective cohort study in Taiwanese women.

Hsiao FY, Huang WF, Chen YM, Wen YW, Kao YH, Chen LK, Tsai YW.

Clin Ther. 2011 Nov;33(11):1659-67. doi: 10.1016/j.clinthera.2011.09.006. Epub 2011 Oct 22.

PMID:
22018450
20.

Health-economic comparison of three recommended drugs for the treatment of osteoporosis.

Brecht JG, Kruse HP, Möhrke W, Oestreich A, Huppertz E.

Int J Clin Pharmacol Res. 2004;24(1):1-10.

PMID:
15575171

Supplemental Content

Support Center